Quote | Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)
Last: | $3.20 |
---|---|
Change Percent: | -1.57% |
Open: | $3.23 |
Close: | $3.20 |
High: | $3.2875 |
Low: | $3.1 |
Volume: | 109,318 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)
2024-04-18 07:00:23 ET More on AbbVie AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore Ab...
2024-04-15 14:15:36 ET More on Reviva Pharmaceuticals Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Fin...
Message Board Posts | Reviva Pharmaceuticals Holdings Inc. (NASDAQ:RVPH)
Subject | By | Source | When |
---|---|---|---|
did everybody leave because it got too expensive | ernie44 | investorshub | 02/05/2023 4:40:06 PM |
you can expect a financing in the first | tootalljones | investorshub | 11/16/2022 11:30:31 PM |
No idea | Alan Brown | investorshub | 11/06/2022 3:54:34 AM |
What happened? | govprs | investorshub | 11/04/2022 8:57:45 PM |
Is this stock going to replicate the rally | Alan Brown | investorshub | 11/04/2022 9:50:58 AM |
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-labe...
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024;...